Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Schedules in Bone-Predominant Metastatic Breast Cancer
NCT00410813Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Mar 2007
- Primary completion
- Jan 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in breast cancer, sponsored by SWOG Cancer Research Network. Started Mar 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00410813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410813.